10 February 2026 Stories of discovery: genetics of PVD Presented at PVRI 2026 Congress by Richard Trembath, King's College London Members Only Member content Register Or Login to view
10 February 2026 The evolution of PH: Tales from medical history Presented at PVRI 2026 Congress by Richard Trembath, King's College London Members Only Member content Register Or Login to view
10 February 2026 Cellular senescence & PH: divergent roles & emerging targets Presented at PVRI 2026 Congress by Serge Adnot, University of Paris East Creteil & Justus Leibig University Members Only Member content Register Or Login to view
10 February 2026 Platelet activation & macrophage recruitment drive vascular dysfunction in a murine model of sickle cell PH Presented at PVRI 2026 Congress by Daniel Colon Hidalgo, University of Colorado Congresses & Symposia
10 February 2026 KEYNOTE: Mitochondrial & metabolic modulators for PH: opportunities & challenges Presented at PVRI 2026 Congress by Anna Hemnes, Vanderbilt University Medical Center Congresses & Symposia
10 February 2026 Beyond sotatercept, what is the future of TGFb/activin signaling in PAH? Presented at PVRI 2026 Congress by Paul Yu, Mass General Brigham Congresses & Symposia
10 February 2026 Sotatercept impairs right ventricular function: insights from multi-center preclinical studies Presented at PVRI 2026 Congress by Sarah-Eve Lemay, Laval University Congresses & Symposia
10 February 2026 Vascular remodeling effects: how else does sotatercept work? Presented at PVRI 2026 Congress by Ardeschir Ghofrani, JuJustus-Liebig-Universität Gießen Congresses & Symposia
10 February 2026 Sotatercept: from clinical trials to real world data & pearls from practice Presented at PVRI 2026 Congress by Ioana Preston, Lahey Hospital & Medical Center Congresses & Symposia
5 February 2026 A Case of IgG4-Related Disease Developing During Long-Term High-Dose Intravenous Epoprostenol Therapy in a Patient With Idiopathic Pulmonary Arterial Hypertension Long-term intravenous (IV) epoprostenol is a key therapy for pulmonary arterial hypertension (PAH); however, rare immune-mediated conditions occurring during therapy remain incompletely characterised. Pulmonary Circulation
